| Literature DB >> 34726349 |
Nicklas Vinter1,2,3, Pia Cordsen3, Gregory Y H Lip4,5, Emelia J Benjamin6,7, Ludovic Trinquart8, Søren Paaske Johnsen3, Lars Frost1,2.
Abstract
AIMS: Atrial fibrillation (AF) constitutes a major burden to health services, but the importance of incident AF in patients with heart failure (HF) is unclear. We examined the associations between incident AF and hospital utilization in patients with HF. METHODS ANDEntities:
Keywords: Atrial fibrillation; Healthcare; Heart failure; Hospitalizations
Mesh:
Year: 2021 PMID: 34726349 PMCID: PMC8712819 DOI: 10.1002/ehf2.13668
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Characteristics of HF patients with incident AF and matched referents at index date
| AF cases | Referents | |
|---|---|---|
| Socio‐demographics | ||
| Age (years), mean (SD) | 73.7 (11.4) | 73.6 (11.3) |
| Female sex, | 1295 (29.0) | 5153 (29.0) |
| Family income | 23 097 (19 283–31 120) | 23 439 (19 434–31 453) |
| Highest completed education, | ||
| Group 1 | 2199 (51.5) | 8947 (52.4) |
| Group 2 | 1544 (36.2) | 6170 (36.1) |
| Group 3 | 528 (12.4) | 1964 (11.5) |
| Lifestyle factors, | ||
| Elevated alcohol consumption | 362 (9.5) | 1237 (8.1) |
| Smoking status | ||
| Never | 1065 (26.7) | 4101 (25.2) |
| Former | 1857 (46.6) | 7532 (46.3) |
| Current | 1064 (26.7) | 4636 (28.5) |
| Clinical data, | ||
| LVEF | ||
| <25% | 1076 (24.7) | 3628 (20.8) |
| 25–40% | 2671 (61.4) | 11 161 (64.1) |
| >40–49% | 296 (6.8) | 1314 (7.6) |
| ≥50% | 311 (7.1) | 1302 (7.5) |
| NYHA class | ||
| I | 499 (12.7) | 2729 (16.7) |
| II | 2361 (59.9) | 9989 (61.2) |
| III/IV | 1082 (27.5) | 3593 (22.0) |
| Time since HF (years), median (Q1‐Q3) | 1.2 (0.2–3.5) | 1.2 (0.4–3.4) |
| Age at HF, mean (SD) | 71.5 (11.4) | 71.4 (11.4) |
| History of co‐morbidity, | ||
| Myocardial infarction | 1404 (31.5) | 5946 (33.4) |
| Any stroke/TIA | 697 (15.6) | 1950 (11.0) |
| Diabetes mellitus | 956 (21.4) | 3149 (17.7) |
| COPD | 696 (15.6) | 2029 (11.4) |
| Hypertension | 2100 (47.1) | 7562 (42.5) |
| Chronic kidney disease | 460 (10.3) | 1228 (6.9) |
| Overweight/obesity | 394 (8.8) | 954 (5.4) |
| Modified CCI, | ||
| 0 | 0 | 0 |
| 1–2 | 2070 (46.4) | 10 430 (58.6) |
| 3–4 | 1185 (26.6) | 4292 (24.1) |
| 5–6 | 655 (14.7) | 1979 (10.1) |
| 7–8 | 316 (7.1) | 732 (4.1) |
| ≥9 | 237 (5.3) | 551 (3.1) |
| Current HF medication | ||
| ACE inhibitors/ARBs | 2806 (62.9) | 9475 (53.2) |
| Beta‐blockers | 2669 (56.8) | 8888 (49.9) |
| MRAs | 1036 (23.2) | 3269 (18.4) |
| Loop diuretics | 1925 (43.1) | 4707 (26.4) |
ACE, angiotensin‐converting enzyme; AF, atrial fibrillation; ARBs, angiotensin receptor blockers; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; HF, heart failure; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; SD, standard deviation; TIA, transient ischaemic attack.
We matched each HF patient with incident AF with up to four referents on age at diagnosis of HF, sex, and time since diagnosis of HF. Characteristics were collected at the time of AF diagnosis or corresponding age for referents, except alcohol use, smoking, LVEF, and NYHA, which were collected around the time of HF diagnosis. Missing, N (%): income 36 (0.2%); education: 913 (4.1); alcohol consumption: 3164 (14.2); smoking: 2010 (9.3); LVEF: 506 (2.3); and NYHA: 2012 (9.0).
Defined by the International Classification of Diseases codes.
Defined as fulfilling at least one prescription within 6 months prior to the index date, except loop diuretics for which the period was 3 months. Modified CCI did not include AIDS.
Figure 1Cumulative incidence of first hospital contact after index date. The cumulative incidence accounted for the competing risk of death. AF, atrial fibrillation; HF, heart failure.
Incident AF and time to first hospital contact
| Inpatient contact | Outpatient contact | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence, % (95% CI) | Cumulative incidence ratio | Cumulative incidence, % (95% CI) | Cumulative incidence ratio | |||
| Model 1 | Model 2 | Model 1 | Model 2 | |||
| 30 days after index date | ||||||
| AF cases | 25.3 (24.0–26.7) | 5.36 (4.71–6.11) | 4.76 (4.07–5.58) | 38.3 (36.8–39.7) | 4.73 (4.31–5.18) | 4.33 (3.91–4.81) |
| Referents | 5.2 (4.9–5.5) | 1.00 (ref) | 1.00 (ref) | 10.6 (10.1–11.0) | 1.00 (ref) | 1.00 (ref) |
| 1 year after index date | ||||||
| AF cases | 56.3 (54.8–57.9) | 2.03 (1.95–2.11) | 1.78 (1.71–1.85) | 69.8 (69.4–69.8) | 1.58 (1.54–1.62) | 1.43 (1.39–1.47) |
| Referents | 23.5 (25.8–27.1) | 1.00 (ref) | 1.00 (ref) | 43.1 (42.4–43.9) | 1.00 (ref) | 1.00 (ref) |
AF, atrial fibrillation; CI, confidence interval.
Model 1: adjusted for age at heart failure, time with heart failure, and sex. Model 2: adjusted as Model 1 + family income, educational level, alcohol use, smoking status, left ventricular ejection fraction, New York Heart Association class, history of myocardial infarction, history of stroke, history of diabetes, history of chronic obstructive pulmonary disease, history of hypertension, history of chronic kidney disease, history of obesity, Charlson Comorbidity Index, use of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, use of beta‐blockers, and use of mineralocorticoid receptor antagonists.
Incident AF and number of hospital contacts
| Inpatient contacts | Outpatient contacts | |||||
|---|---|---|---|---|---|---|
| Number of contacts per 1000 risk‐days (95% CI) | Rate ratio (95% CI) | Number of contacts per 1000 risk‐days (95% CI) | Rate ratio (95% CI) | |||
| Model 1 | Model 2 | Model 1 | Model 2 | |||
| 30 days after index date | ||||||
| AF cases | 28.1 (27.1–29.1) | 1.42 (1.36–1.47) | 1.41 (1.36–1.47) | 30.3 (29.4–31.3) | 1.62 (1.57–1.68) | 1.63 (1.57–1.68) |
| Referents | 19.9 (19.6–20.2) | 1.00 (ref) | 1.00 (ref) | 18.7 (18.5–19.0) | 1.00 (ref) | 1.00 (ref) |
| 1 year after index date | ||||||
| AF cases | 8.8 (8.4–9.3) | 2.39 (2.28–2.51) | 2.16 (2.06–2.27) | 10.6 (10.2–11.0) | 2.13 (2.05–2.22) | 1.97 (1.89–2.05) |
| Referents | 3.7 (3.6–3.8) | 1.00 (ref) | 1.00 (ref) | 4.9 (4.9–5.0) | 1.00 (ref) | 1.00 (ref) |
AF, atrial fibrillation; CI, confidence interval.
Model 1: adjusted for age at heart failure, time with heart failure, and sex. Model 2: adjusted as Model 1 + family income, educational level, alcohol use, smoking status, left ventricular ejection fraction, New York Heart Association class, history of myocardial infarction, history of stroke, history of diabetes, history of chronic obstructive pulmonary disease, history of hypertension, history of chronic kidney disease, history of obesity, Charlson Comorbidity Index, use of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, use of beta‐blockers, and use of mineralocorticoid receptor antagonists. Outpatient contacts within 30 days: one patient with four referents was excluded because of an unlikely high number of hospital contacts within 30 days.
Incident AF and proportion of days spent in hospital bed
| Proportion of days spent in a hospital bed, % (95% CI) | Ratio of proportions (95% CI) | ||
|---|---|---|---|
| Model 1 | Model 2 | ||
| 30 days after index date | |||
| AF cases | 8.5 (7.5–9.5) | 10.36 (8.81–12.18) | 10.94 (9.25–12.94) |
| Referents | 0.9 (0.8–1.0) | 1.00 (ref) | 1.00 (ref) |
| 1 year after index date | |||
| AF cases | 5.7 (4.8–7.0) | 5.65 (4.55–7.01) | 5.26 (4.32–6.40) |
| Referents | 1.1 (1.0–1.2) | 1.00 (ref) | 1.00 (ref) |
AF, atrial fibrillation; CI, confidence interval.
Model 1: adjusted for age at heart failure, time with heart failure, and sex. Model 2: adjusted as Model 1 + family income, educational level, alcohol use, smoking status, left ventricular ejection fraction, New York Heart Association class, history of myocardial infarction, history of stroke, history of diabetes, history of chronic obstructive pulmonary disease, history of hypertension, history of chronic kidney disease, history of obesity, Charlson Comorbidity Index, use of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, use of beta‐blockers, and use of mineralocorticoid receptor antagonists.